• Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA). • Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population • Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial

Heart failure with preserved ejection fraction (HFpEF) is a complex disease with pathophysiological heterogeneity, whose treatment is primarily focused on management of symptoms vs treatment of the underlying disease. This talk will highlight some of the multiple pathways being explored in the attempt to bridge the gap between managing comorbidities/symptoms and treating the disease itself.

During this virtual Industry Theater presentation, an expert pulmonologist who specializes in the field of interstitial lung diseases (ILDs) will discuss the complexity of ILD recognition, with a focus on diagnostic criteria and the importance of collaborating with specialists for a timely diagnosis of ILDs